enVVeno Medical Corp Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
enVVeno Medical Corp quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2018 to Q3 2024.
  • enVVeno Medical Corp Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $1.09M, a 23.6% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $1.09M -$336K -23.6% Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $1.18M -$333K -22.1% Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $1.26M -$330K -20.7% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $1.35M -$326K -19.5% Dec 31, 2023 10-Q 2024-10-31
Q3 2023 $1.43M -$324K -18.5% Sep 30, 2023 10-Q 2023-10-26
Q2 2023 $1.51M -$320K -17.5% Jun 30, 2023 10-Q 2023-07-31
Q1 2023 $1.59M -$317K -16.6% Mar 31, 2023 10-Q 2023-04-28
Q4 2022 $1.67M -$314K -15.8% Dec 31, 2022 10-K 2024-02-29
Q3 2022 $1.75M +$1.44M +461% Sep 30, 2022 10-Q 2022-10-27
Q2 2022 $1.83M +$1.44M +372% Jun 30, 2022 10-Q 2022-08-03
Q1 2022 $1.91M +$1.44M +311% Mar 31, 2022 10-Q 2022-04-29
Q4 2021 $1.99M +$1.45M +268% Dec 31, 2021 10-K 2023-03-02
Q3 2021 $312K -$298K -48.9% Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $388K -$294K -43.1% Jun 30, 2021 10-Q 2021-08-11
Q1 2021 $464K -$296K -39% Mar 31, 2021 10-Q 2021-05-12
Q4 2020 $540K -$286K -34.7% Dec 31, 2020 10-K 2022-03-28
Q3 2020 $610K -$283K -31.7% Sep 30, 2020 10-Q 2020-11-17
Q2 2020 $682K -$280K -29.1% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 $760K -$271K -26.3% Mar 31, 2020 10-Q 2020-06-08
Q4 2019 $826K -$274K -24.9% Dec 31, 2019 10-K 2021-03-31
Q3 2019 $893K Sep 30, 2019 10-Q 2019-10-31
Q2 2019 $962K Jun 30, 2019 10-Q 2019-08-05
Q1 2019 $1.03M Mar 31, 2019 10-Q 2019-05-09
Q4 2018 $1.1M Dec 31, 2018 10-K 2019-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.